Bewacyzumab: interakcje
Bewacyzumab (Avastin, Mvasi, Zirabev): 74 udokumentowane interakcje w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 2, umiarkowane: 0, niewielkie: 69, pary, dla których etykieta nie zgłasza istotnej interakcji: 3. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.
Interakcje z etykiety
Poważne interakcje (2)
Postmarketing cases of GI perforation, including fatal cases, were reported when MOVANTIK was used in patients at risk of GI perforation (e.g., infiltrative gastrointestinal tract malignancy, recent gastrointestinal tract surgery, diverticular disease including diverticulitis, ischemic colitis, or concomitantly treated with bevacizumab). (etykieta leku Naloksegol, Ostrzeżenia i środki ostrożności)
- SunitynibPoważna
Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of SUTENT as monotherapy and administered in combination with bevacizumab. (etykieta leku Sunitynib, Ostrzeżenia i środki ostrożności)
Wzmianki o niewielkim znaczeniu (69)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
- PazopanibNiewielka
Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etykieta leku Bewacyzumab, Ostrzeżenia i środki ostrożności)
Nie zgłoszono istotnej interakcji (3)
- IrynotekanBrak interakcji
Effects of VEGZELMA on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel… (etykieta leku Bewacyzumab, Interakcje z innymi lekami)
- KarboplatynaBrak interakcji
Effects of VEGZELMA on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel… (etykieta leku Bewacyzumab, Interakcje z innymi lekami)
- PaklitakselBrak interakcji
Effects of VEGZELMA on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel… (etykieta leku Bewacyzumab, Interakcje z innymi lekami)
Sprawdź, jak Bewacyzumab łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.